Barclays PLC increased its position in Alkermes plc (NASDAQ:ALKS - Free Report) by 108.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 423,931 shares of the company's stock after acquiring an additional 220,893 shares during the period. Barclays PLC owned approximately 0.26% of Alkermes worth $11,867,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new position in shares of Alkermes in the third quarter valued at about $29,000. Signaturefd LLC increased its holdings in Alkermes by 51.2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company's stock worth $34,000 after buying an additional 480 shares during the period. GAMMA Investing LLC raised its position in Alkermes by 83.8% during the 3rd quarter. GAMMA Investing LLC now owns 4,204 shares of the company's stock worth $118,000 after buying an additional 1,917 shares during the last quarter. Archer Investment Corp lifted its stake in Alkermes by 28.6% during the 3rd quarter. Archer Investment Corp now owns 4,500 shares of the company's stock valued at $126,000 after acquiring an additional 1,000 shares during the period. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alkermes in the 2nd quarter valued at $116,000. Institutional investors and hedge funds own 95.21% of the company's stock.
Alkermes Price Performance
Shares of NASDAQ ALKS traded up $0.16 during midday trading on Monday, hitting $30.67. The stock had a trading volume of 2,337,797 shares, compared to its average volume of 1,805,666. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. Alkermes plc has a 1 year low of $22.90 and a 1 year high of $32.88. The company has a market capitalization of $4.96 billion, a PE ratio of 15.65, a P/E/G ratio of 1.03 and a beta of 0.49. The stock has a 50 day simple moving average of $28.54 and a 200-day simple moving average of $27.02.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on ALKS. Mizuho raised their target price on shares of Alkermes from $35.00 to $40.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Stifel Nicolaus upgraded Alkermes from a "hold" rating to a "buy" rating and lifted their price objective for the company from $25.00 to $36.00 in a research note on Tuesday, November 5th. Cantor Fitzgerald lowered their target price on Alkermes from $48.00 to $43.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. HC Wainwright reiterated a "neutral" rating and set a $37.00 price target on shares of Alkermes in a research report on Friday, October 25th. Finally, Piper Sandler restated an "overweight" rating and issued a $37.00 price objective (down previously from $38.00) on shares of Alkermes in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $35.42.
Check Out Our Latest Research Report on ALKS
Insider Buying and Selling at Alkermes
In other Alkermes news, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the sale, the director now owns 23,013 shares in the company, valued at approximately $732,964.05. This represents a 10.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christian Todd Nichols sold 5,208 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the transaction, the senior vice president now owns 60,703 shares in the company, valued at approximately $1,769,492.45. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 147,738 shares of company stock worth $4,572,904. Corporate insiders own 4.89% of the company's stock.
Alkermes Company Profile
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
